ArticleCancer medicine2025
Prevalence of MUTYH Monoallelic Variants in Patients With Hereditary Cancer Using Multigene Panel Testing.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Recurrent Desmoid-Type Fibromatosis of the Breast in a Young Woman With a Monoallelic MUTYH Germline Variant.Cureus · 2026Article
- Clinicopathological and genotypic characteristics of colorectal cancer patients carrying a germline MUTYH mutation.Revista da Associacao Medica Brasileira (1992) · 2026Article
- Prevalence of MUTYH Monoallelic Variants in Patients With Hereditary Cancer Using Multigene Panel Testing.Cancer medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe MUTYH gene is involved in DNA repair and is known for MAP (MUTYH-associated polyposis), an autosomal recessive disorder that predisposes individuals to colorectal cancer (CRC), with a lifetime risk ranging from 40% to 90%. Homozygosity or double heterozygosity (DH) for pathogenic variants (PVs) in MUTYH causes MAP, but several studies suggest that monoallelic PVs may also increase cancer risk, mainly CRC and breast cancer (BC).
methodsWe analyzed MUTYH status in a cohort of 130 patients referred to our familial cancer clinic for suspected hereditary cancer, describing their mutations and clinical features, and comparing the MUTYH mutation rate between our cancer cohort and a group of 150 healthy volunteers. We also described the genetic profile and clinical features of probands relatives, when possible.
results10% of our cancer patients carried a MUTYH PV, while the gene was wild type in all the samples from the control group. The most frequent PVs were c.1187G>A (p.Gly396Asp) and c.536A>G (p.Tyr179cys). We found a double mutation (DM) in 6 patients, with one carrying a DM in MUTYH and the other 5 harboring mutations in MUTYH and other cancer susceptibility genes (CHEK2, BRIP1, MLH1, and BRCA1).
conclusionsThe higher MUTYH mutation rate observed in the cancer cohort compared with the control group; cancer recurrence observed in the heterozygous carriers and in both maternal and paternal family branches of patients harboring a DM suggests that MUTYH PVs may play a role in cancer predisposition and progression, even when monoallelic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.